Telangana is set to announce its Next-Generation Life Sciences Policy 2026–2030 at the World Economic Forum 2026 in Davos, outlining an ambitious roadmap to position the State among the top three global life sciences clusters by 2030. The policy reflects Telangana’s intent to move beyond scale-led growth and emerge as a global leader driven by innovation, value creation, sustainability, and advanced research.

The policy will be unveiled by Chief Minister A. Revanth Reddy, in the presence of Industries and Commerce Minister D. Sridhar Babu, global industry leaders, and senior policymakers. It marks a significant milestone in Telangana’s evolution from a manufacturing powerhouse to a globally competitive hub for frontier life sciences R&D and healthcare innovation.

Telangana currently contributes nearly 40% of India’s pharmaceutical production and hosts more than 250 USFDA-approved manufacturing facilities. The State is also responsible for one-third of the world’s vaccine output, earning global recognition as the Vaccine Capital of the World. Hyderabad is home to leading global pharmaceutical companies such as Eli Lilly, Sanofi, MSD, Novartis, Amgen, and Bristol Myers Squibb, reinforcing its status as a critical node in the global pharma value chain.

A central pillar of the new policy is the development of Green Pharma City, a next-generation, sustainable industrial cluster envisioned to redefine pharmaceutical manufacturing and R&D. Strategically located near the international airport as part of the Bharat Future City project, Green Pharma City will offer seamless connectivity to major industrial corridors and the emerging AI Hub. Designed around a “Work, Live, Learn, and Play” philosophy, the cluster will integrate advanced infrastructure with sustainability measures such as zero liquid discharge, centralized waste management, and energy-efficient systems.

The policy also emphasizes capability-building in frontier areas of life sciences, including advanced therapies, precision medicine, data-led discovery, and biopharma scale-up manufacturing. A flagship initiative under this vision is 1 Bio, a first-of-its-kind growth-phase centre and biopharma scale-up manufacturing facility planned at Genome Valley, Hyderabad.

With over 2,000 life sciences companies, a combined ecosystem valuation of $80 billion, and more than 20 life sciences and MedTech incubators, Telangana today stands as Asia’s leading life sciences hub. Anchored by global platforms such as the WEF’s Centre for the Fourth Industrial Revolution (C4IR–Telangana) in Hyderabad, the State is well positioned to accelerate global collaborations.

Together, the Next-Gen Life Sciences Policy 2026–2030 represents Telangana’s strategic commitment to shaping the future of global healthcare and achieving its ambition of building a $250 billion life sciences economy by 2030.